| Ytd | -3.90% | |
| 1y | 66.62% |
| Open | 12.48 | Prev Close | 12.58 | Low | 12.45 | High | 12.59 | Mkt Cap | 718.13M |
| Vol | 0.00 | Avg Vol | 1.07M | EPS | -2.14 | P/E | -5.88 | Forward P/E | -5.39 |
| Beta | 0.01 | Short Ratio | 12.52 | Inst. Own | 101.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 12.74 | 200-d Avg | 8.32 | 1yr Est | 26.43 |
ATXS News
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the specia
Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) and Astria Therapeutics (NASDAQ: ATXS - G
Astria Therapeutics, Inc. (NASDAQ: ATXS - Get Free Report) shares passed below its fifty day moving
NEW YORK and NEW ORLEANS, Jan. 7, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles
NEW YORK, Dec. 20, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is invest
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan
I maintain a hold rating on Astria Therapeutics with an updated $13 target price following Biocryst'
NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is invest
Astria Therapeutics, Inc. (ATXS) came out with a quarterly loss of $0.55 per share versus the Zacks
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focuse
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focuse
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focuse
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,
ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting th
NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is invest
NEW YORK , Oct. 14, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Ass
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday agreed to acquire Astria Therapeutics, Inc.
MILWAUKEE , Oct. 14, 2025 /PRNewswire/ -- The Ademi Firm is investigating Astria (NASDAQ: ATXS) for
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
BioCryst Pharmaceuticals said on Tuesday it would buy Astria Therapeutics in a cash-and-stock deal v
On Wednesday, 311 stocks hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
During Monday's trading, 1214 companies set new 52-week lows.
Gainers